StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, Lake Street Capital cut their target price on shares of Evogene from $30.00 to $12.00 and set a buy rating on the stock in a research note on Friday, August 23rd.
Read Our Latest Stock Report on Evogene
Evogene Trading Up 3.0 %
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.
Hedge Funds Weigh In On Evogene
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Recommended Stories
- Five stocks we like better than Evogene
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Investors Need to Know to Beat the Market
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.